Test Your Knowledge

A. Framingham Risk Score B. ASCVD Pooled Cohort Equations C. SCORE2/SCORE2-OP D. Reynolds Risk Score

A. Only in patients with premature ASCVD B. At least once in every adult’s lifetime C. Every 5 years in all adults D. Only if LDL-C is uncontrolled

A. In patients with ACS regardless of prior therapy B. In patients at high or very high risk not at LDL-C goal on maximally tolerated statin ± ezetimibe C. In all patients with diabetes regardless of LDL-C D. In patients with low CV risk who prefer oral therapy over statins

A. Hypoglycemia and pancreatitis B. Hyperuricemia and tendon rupture C. QT prolongation and arrhythmia D. Elevated triglycerides and pancreatitis

Featured

What’s new in the 2025 ESC/EAS Guideline Update for Dyslipidaemia Management

The 2025 Focused Update of the 2019 European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Guidelines for the management of dyslipidaemias reviewed the latest evidence and provided new recommendations based on compelling and practice-changing evidence.

Test Your Knowledge

Featured

What’s new in the 2025 ESC/EAS Guideline Update for Dyslipidaemia Management

Your Privacy